EGFR and neoplasm: As we have previously shown, the BATTLE trial data shows TNF and other target genes are tumor promoting in EGFR mutant patients treated with EGFR TKIs, and we confirmed tumor's TNF was elevated by EGFR TKI therapy in vitro, in vivo, and in patients [17].